Adocia: Annual Revenue And Net Cash Position For 2014
Lyon, France, February 17, 2015 - ADOCIA (Euronext Paris: FR0011184241 – ADOC)
announces today its revenue and its cash position for the fourth quarter and full year 2014.
• Cash position and indebtedness
At December 31, 2014, cash and cash equivalents amounted to EUR 49.8 million including the up-front payment of EUR 41 million (USD 50 million), paid by Eli Lilly pursuant to the licensing agreement signed on December 18, 2014. Cash and cash equivalents totaled EUR 19.4 million at December 31, 2013.
Excluding the payment of Eli Lilly, the 2014 burn rate was EUR 10.6 million, net of the French research and development tax credit (Crédit d’Impôt Recherche).
Financial debts at end of December 2014, as well as at the end of December 2013, totaled EUR 2.4 million. They consist essentially of reimbursable advances received from the French agency for innovation Bpifrance Financement (formerly Oséo) related to osteoporosis and insulin projects
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
• Cash position and indebtedness
At December 31, 2014, cash and cash equivalents amounted to EUR 49.8 million including the up-front payment of EUR 41 million (USD 50 million), paid by Eli Lilly pursuant to the licensing agreement signed on December 18, 2014. Cash and cash equivalents totaled EUR 19.4 million at December 31, 2013.
Excluding the payment of Eli Lilly, the 2014 burn rate was EUR 10.6 million, net of the French research and development tax credit (Crédit d’Impôt Recherche).
Financial debts at end of December 2014, as well as at the end of December 2013, totaled EUR 2.4 million. They consist essentially of reimbursable advances received from the French agency for innovation Bpifrance Financement (formerly Oséo) related to osteoporosis and insulin projects
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.